Post-Traumatic Stress Disorder (PTSD)

🔍 Three Things You Likely Didn’t Know About PTSD

1. Most people who experience trauma do not develop PTSD — spontaneous recovery is the norm. Over half of adults experience at least one traumatic event, yet only about 6% develop PTSD (Diamond et al., 2022). The majority recover naturally. Conversion rates are much higher, however, after violent or intentional trauma, or when someone lacks a support system, has a history of difficult life experiences, or developed symptoms suggestive of shock — such as dissociation, intense fear, or helplessness.

2. Your brain may not file traumatic memories as memories at all. Researchers using fMRI found that when people with PTSD recalled sad autobiographical memories, the hippocampus — the brain’s memory-filing system — activated in a shared, predictable pattern across participants. But when they recalled traumatic memories, the hippocampus showed fragmented, individualized activity — as if the brain was not treating them as memories (Perl et al., 2023). This may explain why flashbacks feel as though the trauma is happening now rather than being recalled as something that happened then.

3. Perhaps as much as half of PTSD is preventable, even after trauma. A new intervention has been tested in populations of individuals exposed to severe war-like trauma, and it cut in half the likelihood of developing any mental disorder including PTSD (Acarturk et al., 2022).

---

📋 Overview

Post-traumatic stress disorder (PTSD) is a psychiatric condition that can develop following exposure to a traumatic event — including direct experience, witnessing, learning about trauma to a close family member or friend, or repeated professional exposure (as in first responders). The DSM-5 organizes PTSD into four symptom clusters:

• Intrusion symptoms — recurrent, involuntary, and distressing memories of the trauma; traumatic nightmares; flashbacks (in which the person feels or acts as if the event is recurring); intense psychological or physiological distress at trauma-related cues.
• Avoidance — persistent effortful avoidance of trauma-related thoughts, feelings, or external reminders (people, places, conversations, activities, objects, situations).
• Negative alterations in cognition and mood — inability to recall key aspects of the trauma; persistent negative beliefs about oneself, others, or the world (“I am fundamentally broken,” “No one can be trusted”); persistent distorted blame of self or others; pervasive negative emotional states; markedly diminished interest in activities; feelings of detachment from others; inability to experience positive emotions.
• Alterations in arousal and reactivity — unpredictable irritability and angry outbursts; reckless or self-destructive behavior; hypervigilance; exaggerated startle response; difficulty concentrating; sleep disturbance.

Cognitive symptoms — perceived brain fog, memory dysfunction, and poor attention — are also commonly reported and tend to significantly improve with effective treatment (Sanger et al., 2025).

Symptoms must persist for more than one month and cause clinically significant distress or functional impairment. PTSD affects approximately 6–8% of the U.S. population over a lifetime, with higher rates among women, combat veterans, survivors of sexual assault, and individuals exposed to interpersonal violence.

The neurobiology of PTSD centers on disrupted threat-processing and memory circuits: the amygdala (threat detection) is hyperactive, the prefrontal cortex (which normally calms the alarm) is impaired, and the hippocampus (which timestamps memories) is altered.

---

🧬 Evolutionary Perspective

Some of the core features of PTSD — hypervigilance, being startle-prone, avoidance of danger-associated cues, intrusive memories of threats — map onto survival mechanisms that appear to have been highly adaptive in ancestral environments. After a life-threatening encounter with a predator, a rival group, or a natural disaster, the ability to remain on high alert, to vividly remember the circumstances of the threat, and to avoid similar situations in the future would have conferred a significant survival advantage.

• Hypervigilance and startle — maintaining a heightened state of readiness after a predatory encounter increases the likelihood of detecting and surviving a subsequent one.
• Intrusive re-experiencing — vivid, involuntary rehearsal of the threatening event may function as a form of “threat simulation” that keeps defensive strategies accessible.
• Avoidance learning — strongly avoiding contexts associated with prior danger is one of the most basic and effective survival strategies across species.

In PTSD, these adaptive responses fail to “extinguish” — they persist long after the threat has passed. The brain essentially remains in a wartime posture during peacetime, responding to even mild reminders of the past as though they were present, imminent, and life-threatening dangers.

---

🔀 Subtypes and Presentations

• Classic PTSD — the full symptom picture described above, typically following discrete, identifiable traumatic events. This presentation responds well to established treatments.
• PTSD with dissociative symptoms — a DSM-5 subtype characterized by prominent depersonalization (feeling detached from oneself) or derealization (feeling that the world is unreal or dreamlike), in addition to the core PTSD symptoms. This presentation may reflect a distinct neurobiological profile and can influence treatment approach.
• Complex PTSD (C-PTSD) — recognized in the ICD-11 but not yet in the DSM-5, complex PTSD develops following prolonged, repeated trauma — often interpersonal in nature (chronic childhood abuse, captivity, domestic violence). In addition to core PTSD symptoms, C-PTSD involves pervasive difficulties with emotional regulation, self-concept (persistent shame, feelings of emptiness, identity disturbance), and relational functioning (difficulty trusting, patterns of revictimization or isolation) which often overlap with certain personality disorders.
• Delayed-onset PTSD — in approximately 25% of cases, full PTSD criteria are not met until six months or more after the traumatic event. Subsyndromal symptoms may be present earlier, with the full clinical picture emerging gradually — sometimes triggered by additional life stressors or age-related changes.
• PTSD with prominent somatic features — some patients present primarily with physical symptoms — chronic pain, gastrointestinal complaints, headaches, cardiovascular symptoms — without initially connecting them to traumatic experiences. This presentation is frequently missed by clinicians who are not specifically screening for trauma history.

---

🩺 Diagnosis

A thorough evaluation for PTSD requires sensitivity, clinical expertise, and a structured approach. Key components include:

• Structured clinical interview — the detailed exploration of traumatic experiences is typically done gradually over time, not in the first visit. Building a sense of safety and therapeutic trust comes first — patients should not expect to recount their trauma in detail during an initial evaluation. As the relationship deepens, the interview maps the timeline of symptom development, functional impairment, and safety assessment.
• Standardized assessment tools — the Clinician-Administered PTSD Scale (CAPS-5) and PTSD Checklist for DSM-5 (PCL-5) are useful measures for diagnosis and severity rating, though — as with all standardized tools — they should not be used in isolation without clinical context.
• Differential diagnosis — PTSD must be distinguished from normal acute stress responses, acute stress disorder, adjustment disorders, major depressive disorder, panic disorder, and dissociative disorders. Traumatic brain injury can produce overlapping symptoms and may itself be part of the traumatic experience leading to PTSD — a consideration particularly relevant in military and accident-related contexts.
• Assessment of comorbidities — PTSD rarely occurs in isolation. Common comorbidities include major depression (occurring in roughly 50% of PTSD cases), substance use disorders, other anxiety disorders, and chronic pain syndromes. Identifying these comorbidities is critical.
• Distinguishing PTSD from a normal trauma response — distressing reactions in the days and weeks following trauma are expected and adaptive. PTSD is diagnosed only when symptoms persist beyond one month and cause significant distress or impairment. Not every distressing post-trauma experience requires a clinical label.

---

💊 Treatment Approach

Psychotherapy

Trauma-focused psychotherapy is the first-line treatment for PTSD and produces the strongest outcomes. Medication can help take the edge off so that the intense process of exploring past events can proceed without the severe distress that often leads to early dropout. Response rates typically range from 50–70% for those who complete therapy, with many patients achieving full remission.

The leading evidence-based approaches include:

• Prolonged Exposure (PE) — systematic, controlled re-engagement with trauma memories and avoided situations in a safe therapeutic context. Repeated exposure allows the brain to update its threat assessment and gradually reduces the emotional charge of the memory.
• Cognitive Processing Therapy (CPT) — focuses on identifying and modifying the distorted beliefs about self, others, and the world that develop after trauma.
• Written Exposure Therapy (WET) — a newer modality that can be completed in as few as five sessions. Patients who drop out of treatment never get better — and WET’s dropout rates are one-third to one-half those of PE and CPT, with outcomes that are just as strong for those who complete treatment (Sloan et al., 2022; Sloan et al., 2023). For many patients, this is the most realistic path to recovery.

For complex PTSD and chronic presentations, third-wave cognitive behavioral therapies such as compassion-focused therapy (CFT) and acceptance and commitment therapy (ACT) are useful additions to help address the pervasive shame, emotional dysregulation, and experiential avoidance that trauma-focused exposure alone may not fully resolve.

Medication and Neuromodulation

Pharmacological treatment targets the neurobiological systems disrupted in PTSD. Serotonin-modulating agents are considered first-line pharmacotherapy and are effective for reducing intrusive symptoms, avoidance, emotional numbing, and hyperarousal. These medications typically require 8–12 weeks for full effect in PTSD, and adequate dosing is important — subtherapeutic doses are a common cause of apparent treatment failure.

For specific symptom domains, targeted pharmacological strategies can be valuable. Trauma-related nightmares, hypervigilance, and sleep disturbance, in particular, often respond to agents that modulate adrenergic signaling — reflecting the role of norepinephrine hyperactivity in the hyperarousal features of PTSD.

Other medication classes — including agents that modulate GABAergic, glutamatergic, and endocannabinoid pathways — are areas of active investigation and may be appropriate in specific clinical scenarios.

The horizon is broader still. MDMA-assisted psychotherapy produced striking results in clinical trials, with a substantial proportion of participants no longer meeting PTSD criteria after treatment — likely by temporarily dampening amygdala-driven fear while enhancing the capacity for therapeutic processing. Additional research is underway, and the regulatory path remains active even though the FDA did not approve MDMA in its most recent review. Beyond MDMA, there is growing scientific interest in compounds with roots in ancient indigenous healing traditions across multiple continents that appear to facilitate profound shifts in how traumatic memories are processed. The clinical frameworks for these emerging approaches are still being established.

Neuromodulation approaches — including transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) — represent additional options worth considering, particularly for treatment-resistant presentations or specific symptom clusters.

The right pharmacological approach depends on the individual’s symptom profile, comorbidities, prior treatment history, and preferences.

Integrative and Lifestyle Approaches

Beyond conventional treatment, targeted interventions involving neuroplasticity-promoting strategies, HPA axis regulation, circadian rhythm optimization, gut-brain axis modulation, and specific somatic approaches may meaningfully support recovery from PTSD — particularly when personalized to the individual’s biology, trauma history, and symptom profile.

---

🌱 Outlook

PTSD is a treatable condition. Trauma-focused psychotherapy produces clinically meaningful improvement in approximately 50–70% of patients, and combined treatment with pharmacotherapy can improve these outcomes further.

Recovery from PTSD does not mean forgetting the trauma — it means transforming the memory from something that intrudes into the present as if it is still happening into a coherent, contextualized part of one’s personal history. It means converting raw emotional memories into ones that can be recalled logically, and helpfully in creating a thriving life, without the unmanageable distress. The goal is to reach a state where the memory can be recalled without the emotional and physiological hijacking that characterizes the disorder.

Treatment can be effective even years or decades after the original trauma. For treatment-resistant cases, advanced pharmacological strategies, novel psychotherapeutic approaches, and neuromodulation continue to expand what is achievable.

---

🏥 How to Get Better

At our psychiatry practice, we have extensive experience treating trauma-related conditions including PTSD and bring a thoughtful, evidence-based approach that integrates medication when needed, psychotherapy, and complementary modalities including supplements, neuromodulation, stress management, movement planning, and holistic practices tailored to each patient’s goals.

Ready to get started? Schedule an intake appointment — a thorough evaluation where we clarify your diagnosis, map out your treatment plan, and get everything moving: medication orders, therapy, supplements, and nutrition. Your care begins the same day, not weeks later.

Schedule Your Intake

We offer statewide telehealth services in California and Florida, with in-person appointments available in Los Angeles and Miami. We also regularly assist international patients due to our fluency in Portuguese, Spanish, and Farsi.

---

📚 References

1. American Psychiatric Association. (2013). Diagnostic and Statistical Manual of Mental Disorders (5th ed.). American Psychiatric Publishing.
2. Diamond, P. R., Airdrie, J. N., Hiller, R., Fraser, A., Hiscox, L. V., Hamilton-Giachritsis, C., & Halligan, S. L. (2022). Change in prevalence of post-traumatic stress disorder in the two years following trauma: A meta-analytic study. European Journal of Psychotraumatology, 13(1), Article 2066456.
3. Perl, O., Duek, O., Kulkarni, K. R., Gordon, C., Krystal, J. H., Levy, I., Harpaz-Rotem, I., & Schiller, D. (2023). Neural patterns differentiate traumatic from sad autobiographical memories in PTSD. Nature Neuroscience, 26(12), 2226–2236.
4. Acarturk, C., Uygun, E., Ilkkursun, Z., Carswell, K., Tedeschi, F., Batu, A., … & Barbui, C. (2022). Effectiveness of a WHO self-help psychological intervention for preventing mental disorders among Syrian refugees in Turkey: A randomized controlled trial. World Psychiatry, 21(1), 88–95.
5. Purgato, M., Carswell, K., Tedeschi, F., Acarturk, C., Anttila, M., Au, T., … & Barbui, C. (2021). Effectiveness of Self-Help Plus in preventing mental disorders in refugees and asylum seekers in Western Europe: A multinational randomized controlled trial. Psychotherapy and Psychosomatics, 90(6), 403–414.
6. Sanger, K. L., Sheridan, C. O., Gould, R. L., & Sheridan, H. (2025). Cognitive symptoms in PTSD: Prevalence and improvement with treatment. Psychology Research and Behavior Management, 18, 217–231.
7. Sloan, D. M., Marx, B. P., Resick, P. A., Young-McCaughan, S., Dondanville, K. A., Straud, C. L., … & Peterson, A. L. (2022). Effect of written exposure therapy vs cognitive processing therapy on PTSD symptom severity in US active-duty military personnel. JAMA Network Open, 5(12), e2246921.
8. Sloan, D. M., Marx, B. P., Lee, D. J., & Resick, P. A. (2023). Written exposure therapy vs prolonged exposure therapy in the treatment of PTSD: A randomized clinical trial. JAMA Psychiatry, 80(12), 1230–1238.
9. Pitman, R. K., Rasmusson, A. M., Koenen, K. C., et al. (2012). Biological studies of post-traumatic stress disorder. Nature Reviews Neuroscience, 13(11), 769–787.
10. Brewin, C. R., Gregory, J. D., Lipton, M., & Burgess, N. (2010). Intrusive images in psychological disorders: characteristics, neural mechanisms, and treatment implications. Psychological Review, 117(1), 210–232.